Results 11 to 20 of about 10,699 (192)
Frontiers in Pharmacology, 2023 Oral corticosteroids (OCS) are commonly used for the acute management of severe asthma exacerbations or as maintenance therapy; however, chronic use is associated with significant toxicities, e.g., osteoporosis. In the REal worlD Effectiveness and Safety
Christian Domingo +10 more
doaj +1 more source
Biomedicines, 2022 Severe asthma (SA) is categorized into multiple overlapping phenotypes and clinical characteristics driven by complex mechanistic inflammatory pathways. Mepolizumab is a human monoclonal antibody effectively targeting interleukin-5 in severe eosinophilic
Ruperto González-Pérez +3 more
doaj +1 more source
Health Sciences Review, 2023 Background: Recently, mepolizumab and benralizumab have been approved for the treatment of severe eosinophilic asthma. Objective: Thus, the main objective of the current study was to find out the exact efficacy and safety profile of mepolizumab and ...
Noor Alam, S. Latha, Anoop Kumar
doaj +1 more source
Frontiers in Immunology, 2023 BackgroundEosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterized by asthma, systemic manifestations, and blood and tissue eosinophilia.ObjectiveTo assess the effectiveness and safety of mepolizumab (anti-IL-5) and ...
Santi Nolasco +20 more
doaj +1 more source
Use of Mepolizumab in Children and Adolescents with Asthma in the USA
Journal of Respiration, 2022 Introduction: Pediatric asthma affects 5.5 million US children and is the leading cause of pediatric chronic illness globally. Those with severe asthma have significantly higher healthcare costs compared to those with non-severe disease.
Jaclyn Davis +11 more
doaj +1 more source
Arthritis Research & Therapy, 2023 Objectives To investigate the efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA) and factors contributing to glucocorticoid (GC) discontinuation.
Takashi Yamane, Akira Hashiramoto
doaj +1 more source
Antagonism of cytokine-induced eosinophil accumulation in asthma [PDF]
, 2012 Peer reviewedPublisher ...
Walsh, Garry M.
core +2 more sources
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma [PDF]
, 2013 Peer reviewedPublisher ...
Walsh, Garry Michael
core +2 more sources
Response to mepolizumab treatment is sustained across 4-weekly dosing periods
ERJ Open Research, 2020 Background Mepolizumab (100 mg delivered s.c. every 4 weeks) is indicated for add-on maintenance treatment for patients with severe eosinophilic asthma. Mepolizumab has been shown to reduce exacerbations and the requirement for daily oral corticosteroids,
Ian D. Pavord +8 more
doaj +1 more source
Biologics for the treatment of chronic rhinosinusitis with nasal polyps : state of the art [PDF]
, 2019 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex upper airway disease affecting up to 11% of the population of Western Europe. In these western countries, 85% of the CRSwNP disease reveals a type 2 inflammatory pattern. In the last 15 years,
Bachert, Claus +3 more
core +1 more source